Stryker Corporation (BMV:SYK)
Mexico · Delayed Price · Currency is MXN | Market Cap | 2.09T -19.6% |
| Revenue (ttm) | 474.05B +7.9% |
| Net Income | 65.30B +23.1% |
| EPS | 176.40 +23.4% |
| Shares Out | n/a |
| PE Ratio | 31.49 |
| Forward PE | 18.17 |
| Dividend | 63.06 (1.14%) |
| Ex-Dividend Date | Sep 30, 2026 |
| Volume | 34 |
| Open | 5,490.00 |
| Previous Close | 5,656.74 |
| Day's Range | 5,490.00 - 5,555.00 |
| 52-Week Range | 4,762.11 - 6,866.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Stryker
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally inv... [Read more]
Financial Performance
In 2025, Stryker's revenue was $25.12 billion, an increase of 11.16% compared to the previous year's $22.60 billion. Earnings were $3.25 billion, an increase of 8.45%.
Financial numbers in USD Financial StatementsNews
Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS
SAN FRANCISCO, Oct. 30, 2026 /PRNewswire/ -- On September 8, 2026, investors in Stryker Corporation (NYSE: SYK) saw the price of their shares fall $26.70 (-8.8%) after the company's CFO revealed that ...
Stryker price target lowered to $375 from $420 at RBC Capital
RBC Capital analyst Shagun Singh lowered the firm’s price target on Stryker (SYK) to $375 from $420 and keeps an Outperform rating on the shares. The company delivered the anticipated…
Stryker price target lowered to $340 from $350 at JPMorgan
JPMorgan analyst Robbie Marcus lowered the firm’s price target on Stryker (SYK) to $340 from $350 and keeps an Overweight rating on the shares.
Stryker price target lowered to $290 from $298 at TD Cowen
TD Cowen lowered the firm’s price target on Stryker (SYK) to $290 from $298 and keeps a Hold rating on the shares. The firm said a soft 3Q was expected,…
Stryker price target lowered to $320 from $335 at Evercore ISI
Evercore ISI lowered the firm’s price target on Stryker (SYK) to $320 from $335 and keeps an Outperform rating on the shares.
Stryker price target lowered to $359 from $418 at Needham
Needham analyst Mike Matson lowered the firm’s price target on Stryker (SYK) to $359 from $418 and keeps a Buy rating on the shares. The company’s Q3 revenue and earnings…
Stryker price target lowered to $304 from $316 at BTIG
BTIG lowered the firm’s price target on Stryker (SYK) to $304 from $316 and keeps a Buy rating on the shares after its Q3 earnings and revenue miss. Investors expected…
Stryker downgraded to Hold from Buy at Canaccord
Canaccord analyst Caitlin Roberts downgraded Stryker (SYK) to Hold from Buy with a price target of $300, down from $385. After signaling weakness at a conference last month, Stryker delivered…
Stryker price target lowered to $334 from $385 at Baird
Baird lowered the firm’s price target on Stryker (SYK) to $334 from $385 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results showing…
Stryker price target lowered to $315 from $360 at Citi
Citi lowered the firm’s price target on Stryker (SYK) to $315 from $360 and keeps a Buy rating on the shares. The firm views the company’s Q3 report as “messy.”…
Stryker price target lowered to $390 from $400 at Citizens
Citizens lowered the firm’s price target on Stryker (SYK) to $390 from $400 and keeps an Outperform rating on the shares. Stryker’s Q3 revenue and EPS missed expectations, prompting lower…
Stryker price target lowered to $365 from $375 at Barclays
Barclays lowered the firm’s price target on Stryker (SYK) to $365 from $375 and keeps an Overweight rating on the shares. The firm says the company’s Q3 report does not…
Stryker Earnings Call Transcript: Q3 2026
Organic sales grew 7.7% and adjusted EPS rose 10.3%, but hip and knee softness and vascular supply constraints led to lower FY guidance. Strong capital demand, margin expansion, and new product launches support the longer-term outlook.
Stryker Earnings release: Q3 2026
Stryker released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Stryker Quarterly report: Q3 2026
Stryker has published its Q3 2026 quarterly earnings report on October 29, 2026.
Stryker reports Q3 adjusted EPS $3.52, consensus $3.55
Reports Q3 revenue $6.5B, consensus $6.62B. “We delivered 7.7% organic sales growth and double-digit adjusted earnings growth in the quarter,” said Kevin Lobo, CEO. “While, in absolute terms, this ref...
Stryker sees FY26 adjusted EPS $14.80-$14.90, consensus $14.95
Sees FY26 organic net sales growth in the range of 6.5%-7.0%. Stryker’s (SYK) sales guidance includes a modestly positive pricing impact. Additionally, foreign exchange is expected to have a slightly…
Stryker reports third quarter 2026 operating results
Portage, Michigan, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2026:
Stryker to participate in the 2026 Jefferies Global Healthcare Conference
Portage, Michigan, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Jefferies Global Healthcare Conference on Tuesday, November 17, 2026, at the Waldorf Hilton and ME ...
Stryker completes acquisition of ZuriMED to enhance its shoulder offering
Portage, Michigan, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced it has completed the acquisition of ZuriMED, a privately held company and de...
These 2 dividend stocks are worth owning for a lifetime
A dividend stock earns its place in a long-term portfolio by doing more than mailing shareholders a quarterly check. It needs a business that can fund those payments while investing sufficiently to st...
Stryker says Sonopet 3 receives FDA 510(k) clearance
Stryker (SYK) announced that Sonopet 3, its latest ultrasonic bone and soft tissue removal platform, has received 510(k) clearance from the U.S. FDA. The first clinical cases using Sonopet 3…
Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
Stryker has received FDA 510(k) clearance for Sonopet ® 3 , the latest evolution of its ultrasonic bone and soft tissue removal platform. Developed in collaboration with surgeons, Sonopet 3 delivers e...
Stryker price target lowered to $316 from $358 at BTIG
BTIG analyst Ryan Zimmerman lowered the firm’s price target on Stryker (SYK) to $316 from $358 and keeps a Buy rating on the shares as part of a broader research…
Stryker initiated with an Overweight at Barclays
Barclays initiated coverage of Stryker (SYK) with an Overweight rating and $375 price target The firm rolled out coverage of the medical suppliers and devices group with a Positive rating.